Compare Stocks: GOSS, TLSA, CUE, and INDP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$25.70 -7.0%	$29.37	$4.97 ▼ $45.50	$143.65M	2.47	197,386 shs	269,766 shs
GOSS Gossamer Bio	$0.14 +2.2%	$0.17	$0.11 ▼ $3.87	$36.19M	2.04	43.50 million shs	6.68 million shs
INDP Indaptus Therapeutics	$0.94 -6.4%	$2.47	$0.92 ▼ $8.57	$142.57M	1.18	119,747 shs	335,692 shs
TLSA Tiziana Life Sciences	$1.12 -2.6%	$1.10	$0.87 ▼ $2.35	$144.44M	0.49	795,316 shs	1.62 million shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	-7.02%	-8.99%	-17.52%	+25.80%	-96.51%
GOSS Gossamer Bio	+2.21%	-21.29%	-15.97%	-33.53%	-92.81%
INDP Indaptus Therapeutics	-6.39%	-21.34%	-63.00%	-23.89%	-87.94%
TLSA Tiziana Life Sciences	-2.61%	+10.89%	+4.67%	-30.43%	-40.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$25.70 -7.0%	$29.37	$4.97 ▼ $45.50	$143.65M	2.47	197,386 shs	269,766 shs
GOSS Gossamer Bio	$0.14 +2.2%	$0.17	$0.11 ▼ $3.87	$36.19M	2.04	43.50 million shs	6.68 million shs
INDP Indaptus Therapeutics	$0.94 -6.4%	$2.47	$0.92 ▼ $8.57	$142.57M	1.18	119,747 shs	335,692 shs
TLSA Tiziana Life Sciences	$1.12 -2.6%	$1.10	$0.87 ▼ $2.35	$144.44M	0.49	795,316 shs	1.62 million shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	-7.02%	-8.99%	-17.52%	+25.80%	-96.51%
GOSS Gossamer Bio	+2.21%	-21.29%	-15.97%	-33.53%	-92.81%
INDP Indaptus Therapeutics	-6.39%	-21.34%	-63.00%	-23.89%	-87.94%
TLSA Tiziana Life Sciences	-2.61%	+10.89%	+4.67%	-30.43%	-40.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	1.00	Sell	N/A	N/A
GOSS Gossamer Bio	2.22	Hold	$3.20	2,136.20% Upside
INDP Indaptus Therapeutics	1.00	Sell	N/A	N/A
TLSA Tiziana Life Sciences	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest GOSS, TLSA, CUE, and INDP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/13/2026	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/17/2026	INDP Indaptus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/14/2026	TLSA Tiziana Life Sciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
6/25/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00 ➝ $2.00
5/29/2026	TLSA Tiziana Life Sciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
5/26/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$5.00
5/19/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 8/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$27.47M	3.93	N/A	N/A	$10.08 per share	2.55
GOSS Gossamer Bio	$48.47M	0.69	N/A	N/A	($0.53) per share	-0.27
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	$1.40 per share	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$26.60M	-$27.02	N/A	N/A	N/A	-435.83%	-482.58%	-282.39%	N/A
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
INDP Indaptus Therapeutics	-$20.85M	-$6.33	N/A	N/A	N/A	N/A	-302.89%	-203.49%	N/A
TLSA Tiziana Life Sciences	-$18.43M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	9/18/2026 (Estimated)

Latest GOSS, TLSA, CUE, and INDP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	CUE Cue Biopharma	-$1.69	-$24.14	-$22.45	-$24.14	$3.00 million	$7.88 million
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/13/2026	Q2 2026	INDP Indaptus Therapeutics	-$1.57	-$0.02	+$1.55	-$0.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
INDP Indaptus Therapeutics	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	N/A	3.57	3.57
GOSS Gossamer Bio	N/A	0.53	0.53
INDP Indaptus Therapeutics	N/A	19.49	19.49
TLSA Tiziana Life Sciences	N/A	0.76	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
GOSS Gossamer Bio	81.23%
INDP Indaptus Therapeutics	7.06%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	14.56%
GOSS Gossamer Bio	3.74%
INDP Indaptus Therapeutics	9.94%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	4.20 million	3.59 million	Optionable
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
INDP Indaptus Therapeutics	6	133.24 million	120.00 million	Not Optionable
TLSA Tiziana Life Sciences	8	127.26 million	76.58 million	Optionable

GOSS, TLSA, CUE, and INDP Headlines

Recent News About These Companies

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Acquires $81,292.79 in Stock

August 7, 2026 | insidertrades.com

Insider Buying: Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases 83,807 Shares of Stock

August 6, 2026 | marketbeat.com

Ivor Elrifi Acquires 237,616 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

August 6, 2026 | marketbeat.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Purchases $667,000.00 in Stock

August 6, 2026 | insidertrades.com

Tiziana Life Sciences (NASDAQ:TLSA) CEO Ivor Elrifi Purchases 667,000 Shares

August 5, 2026 | marketbeat.com

Tiziana Life Sciences Ltd.: Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

August 2, 2026 | finanznachrichten.de

Tiziana Life Sciences Says Imaging Results Show Neuroinflammation Reduction in Rare Neurodegenerative Condition

July 31, 2026 | benzinga.com

Tiziana Life Sciences reports reductions in brain inflammation in third MSA patient

July 31, 2026 | proactiveinvestors.com

Tiziana Reports Reduction in Brain Inflammation in Third Multiple System Atrophy Patient Treated with Intranasal Foralumab

July 31, 2026 | finance.yahoo.com

Tiziana Life Sciences (NASDAQ:TLSA) Stock, Short Interest Report

July 13, 2026 | benzinga.com

Tiziana Life Sciences doses last patient in Phase 2a multiple sclerosis trial

June 25, 2026 | proactiveinvestors.com

Tiziana Announces Last Patient Successfully Dosed in its Phase 2 INFORM-MS Trial

June 25, 2026 | globenewswire.com

Why Tiziana Life Sciences Is Back on the Small-Cap Radar?

June 19, 2026 | kalkinemedia.comK

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

June 15, 2026 | globenewswire.com

Tiziana Life Sciences Ltd.: Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 29, 2026 | finanznachrichten.de

Tiziana Life Sciences to Present at the Jefferies Global Healthcare Conference in New York

May 28, 2026 | globenewswire.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data â€“ ICYMI

May 22, 2026 | proactiveinvestors.com

Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

May 22, 2026 | proactiveinvestors.com

Tiziana Life Sciences Stock Rises Over 9% After Multiple Sclerosis Trial Enrollment Update

May 21, 2026 | finance.yahoo.com

Tiziana Life Sciences completes enrollment in Phase 2a multiple sclerosis trial

May 21, 2026 | proactiveinvestors.com

Tiziana Fully Enrolls its Phase 2 Placebo Controlled Multiple Sclerosis Trial

May 21, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, TLSA, CUE, and INDP Company Descriptions

Cue Biopharma NASDAQ:CUE

$25.70 -1.94 (-7.02%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$25.94 +0.25 (+0.95%)

As of 08:16 AM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Gossamer Bio NASDAQ:GOSS

$0.14 +0.00 (+2.21%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$0.15 +0.00 (+3.42%)

As of 08:39 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Indaptus Therapeutics NASDAQ:INDP

$0.94 -0.06 (-6.39%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$0.96 +0.02 (+2.45%)

As of 08:38 AM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Tiziana Life Sciences NASDAQ:TLSA

$1.12 -0.03 (-2.61%)

Closing price 08/18/2026 04:00 PM Eastern

Extended Trading

$1.14 +0.02 (+1.70%)

As of 08:26 AM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOSS, TLSA, CUE, and INDP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOSS, TLSA, CUE, and INDP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOSS, TLSA, CUE, and INDP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, TLSA, CUE, and INDP Company Descriptions

Cue Biopharma NASDAQ:CUE

Gossamer Bio NASDAQ:GOSS

Indaptus Therapeutics NASDAQ:INDP

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GOSS, TLSA, CUE, and INDP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GOSS, TLSA, CUE, and INDP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GOSS, TLSA, CUE, and INDP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GOSS, TLSA, CUE, and INDP Company Descriptions

Cue Biopharma NASDAQ:CUE

Gossamer Bio NASDAQ:GOSS

Indaptus Therapeutics NASDAQ:INDP

Tiziana Life Sciences NASDAQ:TLSA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools